drugset / Trial / NCT00740714

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

NCT00740714

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.

Timeline

Start
2008-12
Primary completion
2011-08
Completion
2011-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme Q10 Other / unclassified 1200 mg Oral
Subject Coenzyme Q10 Other / unclassified 2400 mg Oral
Background Vitamin E Other / unclassified 1200 iu

Indications